The multiple faces of valosin-containing protein-associated diseases: inclusion body myopathy with Paget's disease of bone, frontotemporal dementia, and amyotrophic lateral sclerosis

Angèle Nalbandian, Sandra Donkervoort, Eric Dec, Mallikarjun Badadani, Veeral Katheria, Prachi Rana, Christopher Nguyen, Jogeshwar Mukherjee, Vincent Caiozzo, Barbara Martin, Giles D Watts, Jouni Vesa, Charles Smith, Virginia E Kimonis, Angèle Nalbandian, Sandra Donkervoort, Eric Dec, Mallikarjun Badadani, Veeral Katheria, Prachi Rana, Christopher Nguyen, Jogeshwar Mukherjee, Vincent Caiozzo, Barbara Martin, Giles D Watts, Jouni Vesa, Charles Smith, Virginia E Kimonis

Abstract

Inclusion body myopathy associated with Paget's disease of bone and frontotemporal dementia (IBMPFD) is a progressive, fatal genetic disorder with variable penetrance, predominantly affecting three main tissue types: muscle (IBM), bone (PDB), and brain (FTD). IBMPFD is caused by mutations in the ubiquitously expressed valosin-containing protein (VCP) gene, a member of the AAA-ATPase superfamily. The majority of individuals who develop IBM have progressive proximal muscle weakness. Muscle biopsies reveal rimmed vacuoles and inclusions that are ubiquitin- and TAR DNA binding protein-43 (TDP-43)-positive using immunohistochemistry. PDB, seen in half the individuals, is caused by overactive osteoclasts and is associated clinically with pain, elevated serum alkaline phosphatase, and X-ray findings of coarse trabeculation and sclerotic lesions. FTD diagnosed at a mean age of 55 years in a third of individuals is characterized clinically by comprehension deficits, dysnomia, dyscalculia, and social unawareness. Ubiquitin- and TDP-43-positive neuronal inclusions are also found in the brain. Genotype-phenotype correlations are difficult with marked intra-familial and inter-familial variations being seen. Varied phenotypes within families include frontotemporal dementia, amyotrophic lateral sclerosis, Parkinsonism, myotonia, cataracts, and anal incompetence, among others. Cellular and animal models indicate pathogenetic disturbances in IBMPFD tissues including altered protein degradation, autophagy pathway alterations, apoptosis, and mitochondrial dysfunction. Currently, mouse and drosophila models carrying VCP mutations provide insights into the human IBMPFD pathology and are useful as tools for preclinical studies and testing of therapeutic strategies. In this review, we will explore the pathogenesis and clinical phenotype of IBMPFD caused by VCP mutations.

References

    1. Mol Cell. 2006 May 19;22(4):451-62
    1. J Neurol Neurosurg Psychiatry. 2009 May;80(5):583-4
    1. Mol Cell Biol. 2002 Jan;22(2):626-34
    1. J Neurol Neurosurg Psychiatry. 2008 Jan;79(1):6-11
    1. Traffic. 2002 Aug;3(8):530-6
    1. PLoS Genet. 2011 Feb 03;7(2):e1001288
    1. Methods Mol Biol. 2011;670:1-9
    1. J Neurosci. 2010 Jun 2;30(22):7729-39
    1. Genet Med. 2000 Jul-Aug;2(4):232-41
    1. Nature. 2001 Dec 6;414(6864):652-6
    1. Skeletal Radiol. 2012 Mar;41(3):329-37
    1. Neurobiol Aging. 2000 Nov-Dec;21(6):913-9
    1. Ann Neurol. 2003;54 Suppl 5:S20-3
    1. Hum Mol Genet. 2010 May 1;19(9):1741-55
    1. Am J Med Genet A. 2008 Mar 15;146A(6):745-57
    1. Biochim Biophys Acta. 2008 Dec;1782(12):744-8
    1. Arch Neurol. 2011 Jun;68(6):787-96
    1. Nature. 1997 Jul 3;388(6637):75-8
    1. J Neurol. 2011 Aug;258(8):1494-6
    1. Neurology. 2005 Oct 25;65(8):1304-5
    1. Hum Mol Genet. 2010 Apr 15;19(R1):R38-45
    1. Neuron. 2010 Dec 9;68(5):812-4
    1. Science. 2009 Feb 27;323(5918):1208-1211
    1. Mol Cell. 2009 Feb 27;33(4):517-27
    1. J Mol Med (Berl). 2010 Feb;88(2):155-66
    1. Neuromuscul Disord. 2010 May;20(5):330-4
    1. Biochem Soc Trans. 2008 Feb;36(Pt 1):105-8
    1. Clin Genet. 2007 Nov;72(5):420-6
    1. Ann Indian Acad Neurol. 2010 Dec;13(Suppl 2):S74-80
    1. J Neurol Sci. 2010 Jul 15;294(1-2):43-50
    1. EMBO J. 2000 May 15;19(10):2181-92
    1. J Struct Biol. 2004 Apr-May;146(1-2):44-57
    1. Neurology. 1996 Aug;47(2):571-3
    1. Nat Clin Pract Rheumatol. 2006 May;2(5):270-7
    1. Braz J Med Biol Res. 2011 Apr;44(4):374-80
    1. EMBO Rep. 2010 Jun;11(6):479-85
    1. Am J Pathol. 2007 Jul;171(1):227-40
    1. Neurology. 1998 Dec;51(6):1546-54
    1. Neurology. 2003 Apr 8;60(7):1094-7
    1. Ann Neurol. 2001 Feb;49(2):165-75
    1. J Clin Endocrinol Metab. 1996 Mar;81(3):961-7
    1. Science. 2008 Mar 21;319(5870):1668-72
    1. Nat Cell Biol. 2007 Apr;9(4):379-90
    1. Neuron. 2010 Dec 9;68(5):857-64
    1. Cancer Cell. 2004 Sep;6(3):203-8
    1. Nat Genet. 2004 Apr;36(4):377-81
    1. CNS Neurol Disord Drug Targets. 2010 Jul;9(3):268-78
    1. Clin Neuropathol. 2007 Sep-Oct;26(5):232-40
    1. Science. 2008 Feb 15;319(5865):916-9
    1. Cell. 1998 Mar 6;92(5):603-10
    1. N Engl J Med. 2005 Sep 1;353(9):898-908
    1. Cell. 2001 Nov 30;107(5):667-77
    1. Science. 2009 Feb 27;323(5918):1205-8
    1. Neuromuscul Disord. 2009 May;19(5):308-15
    1. Neuromuscul Disord. 2009 May;19(5):316-23
    1. Hum Mol Genet. 2010 Sep 1;19(17):3440-56
    1. Ann Neurol. 2005 Mar;57(3):457-61
    1. Nat Rev Neurol. 2010 Apr;6(4):191-2
    1. Hum Mol Genet. 2006 Jan 15;15(2):189-99
    1. Biochem Biophys Res Commun. 2007 Mar 9;354(2):459-65
    1. Hum Mol Genet. 2010 Apr 15;19(R1):R46-64
    1. PLoS One. 2010 Oct 05;5(10):
    1. Autophagy. 2010 Oct;6(7):958-60
    1. Mol Biol Cell. 2004 Mar;15(3):1101-11
    1. Genes Dev. 2004 Sep 15;18(18):2195-224
    1. Neuromuscul Disord. 2003 Sep;13(7-8):559-67
    1. Brain. 2007 Feb;130(Pt 2):381-93
    1. Neurology. 1999 Feb;52(3):504-9
    1. Neurology. 2006 Aug 22;67(4):644-51
    1. Nat Neurosci. 2010 Jul;13(7):805-11
    1. Eur J Neurol. 2009 Jun;16(6):745-51
    1. Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13318-23
    1. Neurology. 2009 Aug 25;73(8):626-32
    1. J Clin Invest. 2007 Apr;117(4):889-901
    1. Ann Neurol. 1996 Feb;39(2):166-73
    1. J Biol Chem. 1998 Feb 6;273(6):3562-73
    1. Bioessays. 1995 Jul;17(7):639-50
    1. Neurobiol Aging. 2009 May;30(5):752-8
    1. Cell. 2008 Sep 5;134(5):804-16
    1. Mol Genet Metab. 2001 Dec;74(4):458-75
    1. Neurodegener Dis. 2007;4(5):376-81
    1. Acta Neuropathol. 2005 Sep;110(3):247-54
    1. Nat Cell Biol. 2001 Aug;3(8):740-4
    1. Neuromuscul Disord. 2009 Nov;19(11):766-72
    1. CNS Neurol Disord Drug Targets. 2010 Jul;9(3):305-13
    1. Muscle Nerve. 2008 Jan;37(1):111-4
    1. Hum Mol Genet. 2007 Apr 15;16(8):919-28
    1. Muscle Nerve. 2009 Mar;39(3):389-91

Source: PubMed

3
Abonner